GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoMimetics Inc (NAS:GLYC) » Definitions » Debt-to-EBITDA

GlycoMimetics (GlycoMimetics) Debt-to-EBITDA : -0.02 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is GlycoMimetics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

GlycoMimetics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.74 Mil. GlycoMimetics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.07 Mil. GlycoMimetics's annualized EBITDA for the quarter that ended in Dec. 2023 was $-38.27 Mil. GlycoMimetics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for GlycoMimetics's Debt-to-EBITDA or its related term are showing as below:

GLYC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.06   Med: -0.03   Max: -0.02
Current: -0.02

During the past 13 years, the highest Debt-to-EBITDA Ratio of GlycoMimetics was -0.02. The lowest was -0.06. And the median was -0.03.

GLYC's Debt-to-EBITDA is ranked worse than
100% of 277 companies
in the Biotechnology industry
Industry Median: 1.36 vs GLYC: -0.02

GlycoMimetics Debt-to-EBITDA Historical Data

The historical data trend for GlycoMimetics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlycoMimetics Debt-to-EBITDA Chart

GlycoMimetics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.06 -0.06 -0.03 -0.02 -0.02

GlycoMimetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.02 -0.04 -0.03 -0.02

Competitive Comparison of GlycoMimetics's Debt-to-EBITDA

For the Biotechnology subindustry, GlycoMimetics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlycoMimetics's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlycoMimetics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where GlycoMimetics's Debt-to-EBITDA falls into.



GlycoMimetics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

GlycoMimetics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.742 + 0.067) / -39.121
=-0.02

GlycoMimetics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.742 + 0.067) / -38.268
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


GlycoMimetics  (NAS:GLYC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


GlycoMimetics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of GlycoMimetics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


GlycoMimetics (GlycoMimetics) Business Description

Traded in Other Exchanges
Address
9708 Medical Center Drive, Rockville, MD, USA, 20850
GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.
Executives
Edwin Rock officer: Chief Medical Officer 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Brian M. Hahn officer: CFO C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Daniel M Junius director C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Bruce S Johnson officer: SVP & Chief Commercial Officer 9708 MEDICAL CENTER DRIVE, BETHESDA MD 20850
Chinmaya Rath officer: SVP and Chief Business Officer 9708 MEDICAL CENTER DR., ROCKVILLE MD 20850
Invus Public Equities, L.p. 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Invus Public Equities Advisors, Llc 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Artal Group S.a. 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Artal International S.c.a. 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
S.a. Westend 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Administratiekantoor Westend Stichting 10 percent owner CLAUDE DEBUSSYLAAN, 46, AMSTERDAM P7 1082 MD
Artal International Management S.a. 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Amaury Wittouck 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L2661
Scott D Sandell 10 percent owner
Harout Semerjian director, officer: Chief Executive Officer 300 THE AMERICAN ROAD, C/O IMMUNOMEDICS, INC., MORRIS PLAINS NJ 07950

GlycoMimetics (GlycoMimetics) Headlines